Since cytokines in chemotherapies also alter the toxicity profile (Falkson et al, 1998; Johnston et al, 1998; Stark et al, 1998), future clinical trials might focus on new combinations, different dosages and dose distribution regimens of IL-2 and INF- to increase both efficacy and tolerability for patients with metastatic melanoma. Here, CBLIF is linked to metastatic melanoma.